IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: billkirn who wrote (1138)	7/23/1997 10:26:00 AM
From: Richard Belanger	of 1762

Bill - Apparently, Dr. Hecht has tempered his enthusiasm for IDPH somewhat. The following was in Sunday's SD Union-Tribune: Merrill Lynch analyst Dr. Eric M. Hecht has become warier of Idec Pharmaceuticals now that a phase-three trial of a potential product for rheumatoid arthritis has been halted. The program will be delayed a year, says the analyst, who has reduced his 1999 earnings per share estimate by a nickel to $1.15. "We have reduced our estimated end-user sales (of the product) by one-half to $65 million to $70 million in 2001, says the analyst. Curious that C2B8 wasn't even mentioned, given the panel meets this week. Rich

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next